{"id":999262,"date":"2026-08-31T20:22:36","date_gmt":"2026-09-01T00:22:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/"},"modified":"2026-08-31T20:22:36","modified_gmt":"2026-09-01T00:22:36","slug":"telix-appoints-david-gill-as-chair","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/","title":{"rendered":"Telix Appoints David Gill as Chair"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>David Gill appointed Chair of the Telix Board, effective immediately.<\/li>\n<li>Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair.<\/li>\n<li>Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair.<\/li>\n<\/ul>\n<p align=\"justify\">MELBOURNE, Australia and INDIANAPOLIS, Sept.  01, 2026  (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d or the \u201cCompany\u201d) today announces that David Gill has been appointed Chair of the Board, effective immediately.<\/p>\n<p align=\"justify\">Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company\u2019s Board expansion and succession planning<sup>1<\/sup>, with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark Nelson, who has served as interim Chair and will remain on the Board as a Non-Executive Director.<\/p>\n<p align=\"justify\">Mr. Gill is a life sciences executive with over 35 years\u2019 experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceutical development, manufacturing and supply chain) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc., and huMannity Medtec.<\/p>\n<p align=\"justify\">Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turnaround strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (acquired by Boston Scientific), INC Research (now Syneos Health), and CTI Molecular Imaging (acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.<\/p>\n<p align=\"justify\">Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said, \u201cI am delighted to welcome David as Chair of Telix. His global life sciences leadership \u2013 including extensive experience in radiopharmaceuticals \u2013 along with financial and capital markets expertise, will be invaluable as Telix continues to scale. I would also like to thank Mark for his leadership as interim Chair and look forward to his continued contribution as a Non-Executive Director.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>Telix Pharmaceuticals Limited <\/strong>\n      <\/p>\n<p align=\"justify\">Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease.<\/p>\n<p align=\"justify\">Telix&#8217;s commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix\u00ae (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S. and Gozellix\u00ae (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and\u00a0Drug\u00a0Administration (FDA). The Company&#8217;s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials:\u00a0TLX591-Tx\u00a0(lutetium-177 (<sup>177<\/sup>Lu) rosopatamab tetraxetan)\u00a0in prostate cancer, TLX101-Tx\u00a0(<sup>131<\/sup>I-iodofalan)\u00a0in recurrent glioblastoma,\u00a0and\u00a0TLX250-Tx\u00a0(lutetium (<sup>177<\/sup>Lu)\u00a0girentuximab\u00a0tetraxetan)\u00a0in kidney cancer,\u00a0additionally\u00a0complemented by a deep pipeline of next generation candidates.<\/p>\n<p align=\"justify\">Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_I_0up0g20jC0Z1_6Szn-mnytOOYugdJRKTjaZocndLYDL0EAflW8rZsYNIcgmALr4wmSmlqsdcyzEjuHo9HdP7xH0c2nwi3xmW_g1fPVnM=\" rel=\"nofollow\" target=\"_blank\">www.telixpharma.com<\/a> or follow Telix on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KWf4JZEMU8qx0ReCglxCQPjRtcCG0eqiaCRAzTDsjO80PlCKJGNMMxL28CtD89PCAcWhukWoE_THyOYzXnj9mq7DaWLmjsfisE4clHcM40=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MA0SIWmEGWGIx62-A-4DvOWX457un7OnR5nnbLxZm-CNrHb0ewAcznruzwSrzTDrKjVG2wbZPqqwqapsdhckCg==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sYh2C_inPIvpLb-7moCbETYHAagg2HJ5V9i-IB0ozk7pi8bY2cc7wrnyM6_8yfMC1ytp8h1EixjH6eCTGWak0Uf1jmbxWQ0nkI7aiiu7WkY=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations<\/strong><\/p>\n<p>Annie Kasparian<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-R2wV8k3oc27XeC0nZWiEorVxKHCjH4Iw3gzdRATitnL1dQct7G3mQMdnwe_Ef5xLEiyJzZ0tPpicszIjA9wB7spG7SfSH865Oq4TqAU4tu75-NsIgTTtViTQYdXTtXVJklVv3yp-NugfeHoHzMgvQ==\" rel=\"nofollow\" target=\"_blank\">annie.kasparian@telixpharma.com<\/a><\/p>\n<p>Charlene Jaw<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ynDbvdStenpOG0Aa0dsDA2eQGNYL1m0kKTxAOvcWzr-IRCx37ZzBqrtKPMVVHcnNeMmECYupKEHUUc5gxxv8sVmANeJrzDRp6tWOYux5KExAsvsZWtNn4XCQkPO0Dda8\" rel=\"nofollow\" target=\"_blank\">charlene.jaw@telixpharma.com<\/a><\/p>\n<p>\n        <em>This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.\u00a0<\/em>\n      <\/p>\n<p align=\"center\">Legal Notices<\/p>\n<p align=\"center\">\n        <em>Cautionary Statement Regarding Forward-Looking Statements.\u00a0 <\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <em>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as \u201cmay\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cplan\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201coutlook\u201d, \u201cforecast\u201d and \u201cguidance\u201d, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix\u2019s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix\u2019s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix\u2019s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix\u2019s preclinical and clinical trials, and Telix\u2019s research and development programs; Telix\u2019s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix\u2019s product candidates, manufacturing activities and product marketing activities; Telix\u2019s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix\u2019s product candidates, if or when they have been approved; Telix\u2019s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix\u2019s expenses, future revenues and capital requirements; Telix\u2019s financial performance; developments relating to Telix\u2019s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix\u2019s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix\u2019s product candidates, if and after they have been approved. Telix\u2019s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>\u00a92026 Telix Pharmaceuticals Limited. All rights reserved.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>_____________________________<br \/><\/em><br \/>\n        <sup>1<\/sup><br \/>\n        <sub>Telix ASX disclosure April 2, 2026.<\/sub>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDQ5MzhhYzEtZTQ3OS00YjY1LThmZGEtOGI1NjI4NmUwNmZiLTEwOTQ4MTMtMjAyNi0wOC0zMS1lbg==\/tiny\/Telix-Pharmaceuticals-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d or the \u201cCompany\u201d) today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company\u2019s Board expansion and succession planning1, with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Telix Appoints David Gill as Chair&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-999262","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Telix Appoints David Gill as Chair - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix Appoints David Gill as Chair - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d or the \u201cCompany\u201d) today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company\u2019s Board expansion and succession planning1, with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark &hellip; Continue reading &quot;Telix Appoints David Gill as Chair&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T00:22:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix Appoints David Gill as Chair\",\"datePublished\":\"2026-09-01T00:22:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/\"},\"wordCount\":1210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/\",\"name\":\"Telix Appoints David Gill as Chair - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\",\"datePublished\":\"2026-09-01T00:22:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-appoints-david-gill-as-chair\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix Appoints David Gill as Chair\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix Appoints David Gill as Chair - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/","og_locale":"en_US","og_type":"article","og_title":"Telix Appoints David Gill as Chair - Market Newsdesk","og_description":"David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, \u201cTelix\u201d or the \u201cCompany\u201d) today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company\u2019s Board expansion and succession planning1, with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark &hellip; Continue reading \"Telix Appoints David Gill as Chair\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-01T00:22:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix Appoints David Gill as Chair","datePublished":"2026-09-01T00:22:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/"},"wordCount":1210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/","name":"Telix Appoints David Gill as Chair - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=","datePublished":"2026-09-01T00:22:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxOTAyOSM3ODA5ODUwIzIwODMyNDI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-appoints-david-gill-as-chair\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix Appoints David Gill as Chair"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=999262"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/999262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=999262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=999262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=999262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}